Single-Use Upstream Bioprocessing Technology / Equipment Market by Type of Product, Scale of Operation and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035
INTRODUCTION On an average, around 50 drugs are approved by the US Food and Drug Administration (US FDA) annually. Further, studies indicate that more than 100,000 tons of pharmaceutical products are consumed globally per year.
New York, March 31, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Single-Use Upstream Bioprocessing Technology / Equipment Market by Type of Product, Scale of Operation and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035" - https://www.reportlinker.com/p06249705/?utm_source=GNW
, In addition, over the next five years, the global pharmaceutical market is projected to grow at a CAGR of 4.7%, with global drug sales anticipated to raise revenues worth USD 1.5 trillion in 2023. This continuously growing pipeline of pharmaceutical drug products has inadvertently led to an increase in the demand for their associated primary and secondary packaging solutions. Specifically, pharmaceutical secondary packaging is a vital step in the product supply chain as it encloses life-saving drugs and therapies, preserving the identity, quality, integrity and stability of the packaged drug product. It also plays a key role in marketing and brand projection for a product. However, the process of secondary packaging usually involves time consuming and complex activities, such as blister carding, thermoforming, labeling, kitting, assembly and cold chain storage (for temperature sensitive biologics). Other key challenges faced by developers are limiting variability in packaging materials and ensuring compliance to stringent regulatory guidelines (for packaging designs). Considering the aforementioned concerns, many pharmaceutical players now prefer to collaborate with qualified packaging providers that offer non-traditional packaging solutions and have the required capabilities to create unique packaging designs, in a cost and time effective manner.
As per the CDMO Outsourcing Survey conducted by Nice Insight, specifically for clinical and commercial scale operations, nearly 60% of the pharmaceutical companies currently outsource their primary packaging needs, while 43% of the players outsource their secondary packaging requirements. At present, more than 160 companies offer secondary packaging solutions to the firms engaged in the pharmaceutical sector. Further, several recent advancements in packaging designs, technologies and materials have enabled service providers to offer a wide range of user-friendly pharmaceutical secondary packaging solutions. In addition, substantial expansions, mergers and acquisitions, and partnerships have been reported in this market as service providers strive to become one-stop-shops, in order to cater to the diverse needs of their clients engaged in the healthcare industry. Driven by the ongoing innovation in this field, continuous growth in the pharmaceutical drugs pipeline and a steady rise in drug approvals, the pharmaceutical secondary packaging market is likely to witness positive growth in the foreseen future.
*SCOPE OF THE REPORT*
The ‘Pharmaceutical Secondary Packaging Market – Distribution by Type of Secondary Packaging (Boxes, Cartons and Pouches), Type of Primary Packaging Packed (Ampoules, Blister Packs, Bottles, Cartridges, Syringes and Vials) and Key Geographies (North America, Europe, Asia-Pacific, MENA, Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035’ report features an extensive study of the current market landscape and future potential of the pharmaceutical secondary packaging market. The study features an in-depth analysis, highlighting the capabilities of pharmaceutical secondary packaging providers.
*Amongst other elements, the report features:*
A detailed overview of the overall landscape of companies offering secondary packaging solutions to the pharmaceutical and biotechnology industries, along with information on several relevant parameters, such as their year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific and rest of the world) and scale of operation (preclinical, clinical and commercial). The chapter also covers details related to the type of service provider (one-stop-shop service providers and stand-alone service providers), type of secondary packaging offered (cartons, boxes and others), type of primary packaging packed (blisters, vials, bottles, conventional syringes, ampoules, prefilled syringes and others), type of molecule packed (biologics, small molecules and unspecified), type of finished dosage form packed (solids, liquids / injectables, semi-solids, powders and others) and type of additional service(s) offered (labeling, serialization, kitting and cold-chain storage).
An insightful competitiveness analysis of the pharmaceutical secondary packaging providers, based on supplier power (in terms of years of experience), company competitiveness (type secondary packaging offered, type of primary packaging packed, type of molecule packed, type of finished dosage form packed, and type of additional services offered) and their respective scale of operation.
An analysis of recent partnerships inked between stakeholders engaged in this domain, during the period 2018-2021, covering acquisitions, manufacturing and packaging agreements, service alliances, packaging agreements, distribution agreements, technology utilization agreements and other related agreements. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership, type of molecule packed, type of finished dosage form packed and most active players (in terms of number of partnerships). It also highlights the regional distribution of the partnership activity witnessed in this market.
A detailed analysis of the recent expansions undertaken by various pharmaceutical secondary packaging providers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), scale of operation, type of primary packaging packed, type of molecule packed, type of finished dosage form packed, company size, location of headquarters, location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution (region-wise and country-wise).
An in-depth analysis to estimate the current and future demand for pharmaceutical secondary packaging, based on several relevant parameters, such as type of secondary packaging (boxes, cartons and pouches), type of primary packaging packed (ampoules, blister packs, bottles, cartridges, syringes and vials) and key geographical regions (North America, Europe, Asia-Pacific, MENA, Latin America and rest of the world), for the period 2022-2035.
Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) engaged in offering pharmaceutical secondary packaging solutions, across North America, Europe and Asia-Pacific. Each profile provides an overview of the company, featuring information on the year of establishment, number of employees, location of their headquarters, key executives, details related to its secondary packaging offerings, recent developments, and an informed future outlook.
One of the key objectives of the report was to evaluate the current opportunity and future potential associated with the pharmaceutical secondary packaging market, over the coming 13 years. We have provided an informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as [A] type of secondary packaging (boxes, cartons and others), [B] type of primary packaging packed (ampoules, blister packs, bottles, cartridges, syringes and vials) and [C] key geographical regions (North America, Europe, Asia-Pacific, MENA, Latin America and rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
Jake Aspinall (Commercial Director, Active Pharma Supplies)
Silvio Del Deo (Managing Director, Depo Pack)
Joe Luke (Vice President, Sales and Marketing, Reed-Lane)
*RESEARCH METHODOLOGY*
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views
While the focus has been on forecasting the market over the coming 15 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
KEY QUESTIONS ANSWERED
Who are the leading players offering single-use upstream bioprocessing technologies?
What are the different application areas where single-use upstream bioprocessing technologies can be used?
In which regions majority of the single-use upstream bioprocessing technology providers are located?
What is the relative competitiveness of different single-use upstream bioprocessing technologies?
What are the key features of single-use bioreactors?
How has the intellectual property landscape of single-use upstream bioprocessing technologies, evolved over the years?
What is the current demand and supply of biologics manufacturing through single-use upstream bioprocessing technology?
How is the current and future opportunity likely to be distributed across key market segments?
*CHAPTER OUTLINES*
Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the single-use upstream bioprocessing technology market and its likely evolution in the short to mid-term and long term.
Chapter 3 provides a general introduction to bioprocessing industry, covering details related to the current trends in the domain. The chapter provides details on the historical evolution of single-use technology and different types of single-use equipment. It emphasizes on various advantages and key challenges associated with the single-use technologies. In addition, it discusses implementation strategies of the single-use upstream bioprocessing technology and future prospects.
Chapter 4 provides a detailed assessment of the overall market landscape of single-use bioreactors based on a number of relevant parameters, such as scale of operation (lab, clinical and commercial), type of cell culture system (2D culture and 3D culture), type of cell culture (mammalian, insect, microbial, viral, plant and others), type of molecule (vaccine, monoclonal antibody, recombinant protein, stem cell, cell therapy, gene therapy and others), key features (touch screen, remote monitoring, build-in system control sensors, electronic log record, alarm system), application area (stem cell research, cancer research, regenerative medicine, drug discovery and others) and end users (pharma / biopharma, contract manufacturing organization, contract research organization and academic institutes). In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
Chapter 5 provides a detailed assessment of the overall market landscape of single-use mixers based on a number of relevant parameters, such as scale of operation (lab, clinical and commercial), type of mixing system (liquid / liquid, solid / liquid and powder / liquid), type of molecule (vaccines, biologics, biosimilars and monoclonal antibody), key features (visual display / touch screen, ease to use / scalability, build-in system control sensors and process automation) and application area (media preparation, formulation, buffer preparation, viral inactivation and others). In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
Chapter 6 provides a detailed assessment of the overall market landscape of single-use sensors, based on several relevant parameters, such as type of sensor (conductivity, flow, pH, pressure and temperature), type of bioprocessing, measurement range, operating temperature, sterilization technique, material used) and application area. In addition, the chapter presents details of the companies involved in the development of single-use sensors, including information on their year of establishment, company size, and geographical presence.
Chapter 7 features a tabulated section presenting the overall market landscape of other single-use technologies, such as filters, sampling systems and connectors.
Chapter 8 features a detailed competitiveness analysis of single-use bioreactors, single-use mixers and single-use sensors, taking into consideration several relevant parameters. For single-use bioreactors, the parameters taken into account include the product applicability (type of cell culture, type of molecule and application area) and product strength (type of cell culture system, scale of operation and key features). For single-use mixers, the parameters taken into account include the product applicability (type of mixing system, type of molecule and application area) and product strength (scale of operation). For single-use sensors, the parameters taken into account include the product specificity (minimum operating temperature, maximum operating temperature, type of calibration and type of sterilization technique) and product strength (application area and type of bioprocessing).
Chapter 9 features tabulated profiles of the key players providing single-use upstream bioprocessing technologies, which are headquartered in North America. Each profile includes an overview of the company, information on the financial performance (if available), service portfolio, product portfolio, recent developments, and an informed future outlook.
Chapter 10 features tabulated profiles of the key players providing single-use upstream bioprocessing technologies, which are headquartered in Europe. Each profile includes an overview of the company, information on the financial performance (if available), service portfolio, product portfolio, recent developments, and an informed future outlook.
Chapter 11 features tabulated profiles of the key players providing single-use upstream bioprocessing technologies, which are headquartered in Asia-Pacific. Each profile includes an overview of the company, information on the financial performance (if available), service portfolio, product portfolio, recent developments, and an informed future outlook.
Chapter 12 presents an in-depth analysis of various patents that have been filed / granted for single-use upstream bioprocessing technology, till December 2021, highlighting key trends associated with these patents, across type of patents, publication year, application year, issuing authorities involved, type of organizations, emerging focus area, patent age, CPC symbols, leading patent assignees (in terms of number of patents granted / filed), patent characteristics and geography. It also includes a detailed patent benchmarking and an insightful valuation analysis.
Chapter 13 provides a detailed brand positioning analysis of the key industry players (including single-use bioreactor developers, single-use mixers developers and single-use sensors developers), highlighting the current perceptions regarding their proprietary products by taking into consideration several relevant aspects, such as experience of the manufacturer, number of products offered, product diversity, and number of patents published.
Chapter 14 presents an insightful analysis of the cost and time saving potential of single-use upstream bioprocessing technology.
Chapter 15 provides an informed estimate on the current and future demand and supply of biologics manufactured using single-use upstream bioprocessing technologies, for the period 2022-2035.
Chapter 16 features a comprehensive market forecast analysis, highlighting the future potential of the market till 2035, based on multiple parameters, such as overall upstream bioprocessing equipment market, and share of single-use technology. It includes an informed estimate of the evolution of the market for the period 2022-2035. We have segregated the current and future opportunity have further been segmented on the basis of [A] scale of operation (preclinical / clinical and commercial), [B] type of product (single-use bioreactors, single-use mixers, single-use media bags, single-use filters, single-use sampling systems, single-use connectors and others), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). It is worth mentioning that we adopted a top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research.
Chapter 17 is the summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the single-use upstream bioprocessing market.
Chapter 18 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the company and details of the interview held with Christopher Brau (R&D Staff Scientist and Engineer, Thermo Fisher Scientific) and Nico Oosterhuis (Technical Director and Co-Owner, Celltainer Biotech).
Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.
Read the full report: https://www.reportlinker.com/p06249705/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001